Swallowable Sponge Cell Sampling Device and Next Generation Sequencing in Detecting Esophageal Cancer in Patients with Low or High Grade Dysplasia, Barrett Esophagus, or Gastroesophageal Reflux Disease

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Status: Active


This pilot clinical trial studies how well a swallowable sponge cell sampling device and next generation sequencing work in detecting esophageal cancer in patients with low or high grade dysplasia, Barrett esophagus, or gastroesophageal reflux disease. Checking biomarkers in abnormal esophageal cells using a swallowable sponge cell sampling device and next generation sequencing may improve diagnosis and treatment of esophageal cancer.

Eligibility Criteria

Inclusion Criteria

  • Ability to understand and the willingness to sign a written informed consent document
  • Patients must be scheduled for a procedure capable of providing a definitive pathologic diagnosis and evaluating for complications of the esophageal sponge on the same day as the study procedure, either upper endoscopy or surgical esophagectomy
  • One of the following inclusion criteria must be true for patient to be eligible for enrollment:
  • Subjects with known esophageal cancer (adenocarcinoma or squamous cell carcinoma)
  • Subjects with a history of low or high grade dysplasia
  • Subjects with risk factors for esophageal malignancy including Barrett’s esophagus and gastroesophageal reflux disease (GERD)

Exclusion Criteria

  • Subjects that are unable to swallow a tablet/pill
  • Subjects with completely obstructing esophageal cancer
  • Subjects with known or suspected esophageal varices
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Any condition which, in the opinion of the investigator precludes the patient from completion of the study procedure

Locations & Contacts


OHSU Knight Cancer Institute
Status: Active
Contact: James P. Dolan
Phone: 503-494-4937 Email: dolanj@ohsu.edu

Trial Objectives and Outline


I. Determine the sensitivity and specificity of next generation sequencing for the detection of esophageal cancer from esophageal sponge cytology specimens.


I. Determine the ability of next generation gene sequencing (NGS) of esophageal sponge samples to collect an adequate sample to detect mutations that are present in the underlying tissue.

II. Determine the cost associated with esophageal cytology with next generation genome sequencing as a screening tool.

III. Continue to collect safety and tolerability data related to the use of the Oesotest esophageal sponge.

IV. Determine the limitations of esophageal sponge cytology and future needs to improve this technique.

V. Use the data collected to design a larger screening trial to determine the ability of esophageal cytology with next generation sequencing to screen for esophageal cancer in the general population.


Patients undergo cytology specimen collection procedure using a swallowable sponge cell sampling device.

Trial Phase & Type

Trial Phase

No phase specified

Trial Type


Lead Organization

Lead Organization
OHSU Knight Cancer Institute

Principal Investigator
James P. Dolan

Trial IDs

Primary ID STUDY00015499
Secondary IDs NCI-2016-01318
Clinicaltrials.gov ID NCT02890979